BATON ROUGE, La. – Skymount Medical has partnered with Riverside University Health System, or RUHS, Medical Center to conduct the first U.S. clinical trial on the efficacy of COVID-19 oral
Read more about US eager to involve Indian investigators in clinical trials on Coivd: Fauci on Business Standard. Dr Anthony Fauci said his country is eager to involve Indian investigators in global clinical trials to evaluate the safety and efficacy of Covid-19 therapeutics
Observational studies have suggested that increased vitamin D levels may protect against COVID-19. However, these studies were inconclusive and possibly subject to confounding. A study published in PLOS Medicine by Guillaume Butler-Laporte and Tomoko Nakanishi at McGill University in Quebec, Canada, and colleagues suggests that genetic evidence does not support vitamin D as a protective measure against COVID-19. The ability of vitamin D to protect against severe COVID-19 illness is of great interest to public health experts but has limited supporting evidence. To assess the relationship between vitamin D levels and COVID-19 susceptibility and severity, researchers conducted a Mendelian randomization study using genetic variants strongly associated with increased vitamin D levels.
The city-based PNB Vesper Life Sciences has successfully completed phase 2 clinical trials of PNB-001 (GPP-Baladol), its proprietary drug to treat the coronavirus infection and said it will soon move the government for deploying the drug for emergency use. The company, which has its labs in England, had in early September 2020 received the approval from the Drug Controller General (DCGI) to conduct the phase 2 clinical trial of GPP-Baladol in patients with moderate infection of the pandemic with oxygen support. The company on Monday said the clinical trial was initiated in November at BJ Government Medical College and Sassoon General Hospital in Pune, and Victoria Medical College and Research Institute in Bengaluru on 40 patients.